Clinical Case


Dr Sanket Mankad MD, F.I.D-CMC, Vellore Infectious Diseases & HIV Consultant

Case

- 42 year old lady , Uttar Pradesh
- Background of :
- DM Type 2 (Uncontrolled)
- Status post Renal transplant (2019)
- On Tacrolimus, Prednisolone, Valgancyclovir
- Presented with complaints of fever 2 weeks, cough with no expectoration, dyspnea on exertion since 4-5 days
- Worsening right chest pain with inspiration since 2 days

- Physical examination:
- Febrile
- HR: 120/min, BP: 100/60 mm Hg
- SpO2: 95-96%
- Bilateral crepts
- No neurological deficits

- Hb : 9.2 gm%
- TC: 3500/cmm
- DC:65/25/3/2/0
- Platelets: 3.25 lakhs/cmm
- RBS: 450mg/dl
- CRP: 225 mg/L
- CXR: Left mid zone opacity




- Syndromic diagnosis:
- Pneumonia in a immunosuppressed patient v/s Community acquired pneumonia
- Differential diagnosis:
- Pyogenic /Atypical bacterial
- Mycobacterial(M Tb/NTM)
- Invasive aspergillosis

Further progress


- Was started on Beta lactum plus macrolide anti biotics
- No clinical improvement
- Serum Galactomanan: 0.45 mg/l
- 1,3 BDG : <60
- Normal pneumoslide panel
- U/W a HRCT scan

HRCT: Bilateral consolidation



- Underwent CT guided biopsy of the Lung as the lesion was peripheral
- Histopathology: Necrotising granulomatous inflammation
- Tissue Gene Xpert negative
- Tissue fungal c/s negative
- Tissue: Gram positive thin branching filaments s/o Nocadia spp

Gram positive thin branching filaments-Nocardia



Identification by MALDI TOF

TEST	RESULTS	UNIT	BIOLOGICAL REF RANGE	REMARKS	
Identification By MALDI TOF (Mass Spectrometry)					
Specimen	Tissue				
Identification By Maldi TOF (Mass Spectrometry)	Nocardia cyriacigeorgica				
Note	Score: 1.81				

Method: Matrix-assisted laser desorption ionization Time-of-flight (MALDI TOF) Mass spectrometry. Bruker.

ID/DST of Nocardia

TISSUE	
Nocardia cyriacigeorgica	
S (2)	
S (0.5/9.5)	
R (4)	
R (64)	
R (8)	
R (32)	
R (128)	
R (64/32)	
S (1)	
S (8)	
I (2)	
I (2)	
S (0.5)	
S (1)	

Final Diagnosis

• Nocardia cyriacigeorgica pneumonia in Renal allograft recipient /T2D

Further Progress

- She was started on TMP/SMX, Linnezolid oral plus iv Ceftriaxone(2 weeks)
- Gradually improved clinically and radiologically
- Currently on TMP/SMX plus linezolid
- Plan is to give above regimen for 6 months in view of ongoing immunosuppression

Nocardia cyriacigeorgica

JOURNAL OF CLINICAL MICROBIOLOGY, Jan. 2008, p. 265–273

- N. cyriacigeorgica is an emerging pathogenic entity in USA and a rare occurrence in Indian sub continent
- The number of recognized Nocardia species causing infections is also increasing
- Accurate and timely identification of nocardiae is important because the pathogenic potential between species varies and because the species identity provides a critical guide for physicians in the choice of targeted therapy

Amikacin plus a beta-lactam (ceftriaxone or imipenem) are typically added to TMP-SMX to ensure the susceptibility of all Nocardia spp. to at least two antimicrobials

- Because of its distinct and favorable antimicrobial susceptibility pattern, the specific identification of N. cyriacigeorgica may improve clinical management
- However, an optimal management protocol for nocardiosis has not been defined, and guidelines for specific treatment by species are needed

Acknowledgements

- Dr Siddharth Mavani DM (Nephrologist, Marengo CIMS)
- Dr Bhavini Shah/Dr Krutarth Shah MD(Microbiologist, Neuberg Supratech)